Survival disadvantage of male children with retinoblastoma in the United States: Surveillance Epidemiology and End Results (2000–2017) Evidence
Cancer Medicine · 2023-02 · 12 (4) · 4626-4637
DOI: 10.1002/cam4.3967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 31.01.2023. Verfasst von Laurens Holmes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nemours/Alfred I. DuPont Hospital for Children, Office of Health Equity & Inclusion, Health Disparities Science Research, Wilmington, DE, USA. Hauptthemen laut MEDLINE: Retinoblastoma, Retinal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Retinoblastoma is a rare malignancy involving the retina, although, more common among children, with genetic inheritance explaining the incidence as well as acquired forms. The incidence varies among race and sex as well as mortality and survival. The current study aimed to assess retinoblastoma cumulative incidence (CMI), mortality, and survival by sex.
Methods
A retrospective cohort design was used to assess the CMI, mortality, and survival in this pediatric malignancy based on the Surveillance Epidemiology and End Results (SEER) data 2000–2017. The binomial regression model was used to examine sex differentials in mortality, as well as other study variables, while Cox proportional hazard model was used for the survival variability by sex.
Results
The CMI during this period was higher among males relative to females (males n = 249, 56.7%; females n = 190, 43.3%, χ 2 = 2.90, df = 1, p = 0.089). There were sex differences in mortality, with excess mortality observed among males compared to females, risk ratio = 3.40, 95% CI [1.0–15.72]. The survival differences by sex indicated decreased survival among males relative to females, hazard ratio (HR) = 3.39, 95% CI [1.0–15.72]. After controlling for the potential confoundings, namely tumor grade, urbanity, and median income the survival disadvantage of males persisted. Compared to females’, males were more than three times as likely to die, adjusted HR = 3.42, 99% CI [0.37–31.60].
Conclusion
In a representative sample of pediatric retinoblastoma, there was a sex differential in survival with excess risk of dying identified among males relative to females, which may be explained in part by male X‐linkage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nemours/Alfred I. DuPont Hospital for Children, Office of Health Equity & Inclusion, Health Disparities Science Research, Wilmington, DE, USA.
- Biological Science Department, University of Delaware, Newark, NJ, USA.
- Thomas Jefferson University School of Population Health and Medical School, Philadelphia, PA, USA.
- Master of Public Health, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, FL, USA.
- Perelman School of Medicine, University of Pennsylvania Master of Public Health Program, Philadelphia, PA, USA.
ORCID-Profile: Betyna N Berice, Jacqueline A Benson
Zitieren
APA
Holmes, L., Pollack, E., Berice, B. N., Halloran, D. R., Parson, K., Badfford, N. T., Paleaz, L., & Benson, J. A. (2023). Survival disadvantage of male children with retinoblastoma in the United States: Surveillance Epidemiology and End Results (2000–2017) Evidence. Cancer Medicine, 12(4), 4626-4637. https://doi.org/10.1002/cam4.3967
Vancouver
Holmes L, Pollack E, Berice BN, Halloran DR, Parson K, Badfford NT, et al. Survival disadvantage of male children with retinoblastoma in the United States: Surveillance Epidemiology and End Results (2000–2017) Evidence. Cancer Medicine. 2023;12(4):4626-4637. doi:10.1002/cam4.3967
BibTeX
@article{Holmes2023,
author = {Holmes, Laurens and Pollack, Emily and Berice, Betyna N and Halloran, Daniel R and Parson, Kadedrah and Badfford, Nastocia T and Paleaz, Lavisha and Benson, Jacqueline A},
title = {Survival disadvantage of male children with retinoblastoma in the United States: Surveillance Epidemiology and End Results (2000–2017) Evidence},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {4626--4637},
doi = {10.1002/cam4.3967}
}
EUVIMED